Table 1.
Characteristics of all randomized patients in the Japan Clinical Oncology Group study, JCOG 9208
| Treatment arm | Standard‐dose | High‐dose | |
|---|---|---|---|
| No. of enrolled patients | 48 | 49 | |
| Median age in years (range) | 47 (27–55) | 46 (29–55) | |
| Menopause | Pre/post | 34/14 | 38/11 |
| PS | 0/1 | 41/7 | 46/3 |
| No. of positive axillary nodes | Median (range) | 18 (10–46) | 16 (10–49) |
| 10–19 | 28 | 28 | |
| 20– | 20 | 21 | |
| Stage | I | 2 | 2 |
| IIA | 8 | 12 | |
| IIB | 18 | 16 | |
| IIIA | 10 | 9 | |
| IIIB | 10 | 9 | |
| IV | 0 | 1 † | |
| ER | +/–/unknown | 29/19/0 | 25/22/2 |
| PgR | +/–/unknown | 25/22/1 | 22/24/3 |
†
Ineligible. ER, estrogen receptor; No., number; PgR, progesterone receptor; PS, performance status (0 or 1 according to the Eastern Cooperative Oncology Group criteria( 28 )).